ADVERTISEMENT
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1996 entries already.
A method to quickly classify central nervous system (CNS) tumours, combining rapid sequencing and deep-learned AI models, may enable molecular diagnosis in less than 90 minutes, Dutch researchers report.
Try TSKgel UP-SW columns for SEC analysis of biomolecules risk-free for 30 days
A well connected and effective infrastructure, a high density of research and development as well as close networking are of great value, not only to founders. Within the successful healthcare cluster Berlin-Brandenburg, these include numerous technology parks in the region. The parks offer optimal space including state of the art laboratories to start-up and grown-up companies.
Belgian fibrosis specialist Agomab Therapeutics NV has raised US$100m to advance development of its pipeline.
Alzheimers specialist AstronauTx Ltd has closed a £48m Series A financing to create new treatments for Alzheimers diseas
Sino Biological, Inc., is pleased to announce the formal opening of its new Center for Bioprocessing (C4B) in Houston, Texas USA, adjacent to the world-renowned Texas Medical Center.
At the celebration of the 10th anniversary of the Bio-based Industry Consortium (BIC), the student team BioAroma was presented with the BISC-E 2023 award, which comes with €5000 in prize money.
Paris-based Orakl Oncology SA has raised €3m to develop its techbio platform for precision oncology.
Precision medicine tailors therapeutics to individual patients diseases, and is seen as the future of clinical practice. With significant time and financial investments being made in developing therapeutics, the ultimate success of patient-data driven precision therapies hinges on three main factors: the quality of the tissue samples, the associated molecular data, and the analysis used in their development.
French pharma major Sanofi SA will pay US$175m upfront to Janssen Pharmaceuticals, Inc. for commercialisation of a Phase III vaccine against extraintestinal pathogenic E. coli.